Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022 08:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 30, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by...
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 02, 2022 08:09 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product...
Immuneering Announces Participation in September Investor Conferences
August 25, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 10, 2022 16:05 ET
|
Immuneering Corporation
IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022 ...
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
July 06, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
May 26, 2022 17:26 ET
|
Immuneering Corporation
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across...
Immuneering Announces Participation in Upcoming Investor Conferences
May 20, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 10, 2022 06:30 ET
|
Immuneering Corporation
IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed to sensitize resistant tumors to select immunotherapies,...
Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day
May 05, 2022 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...